HelixoMetry, Inc. is a privately held, Silicon Valley based Intellectual Capital Portfolio
* FRACTOGENE PATENT PENDING *
Founder of Helixometry
tel: (408) 891-7187
Aug 1, 2002
FractoGene Patent Pending. Initial offerings outlined, first in a closely held manner.
FractoGene of HelixoMetry is marketed in 7 overlapping Business Models
"Seven Sisters":
(1) Translation Memory Company, Partnership / M/A
(2) "Big Pharma" Pharmaceutical Company, M/A
(3) "Big IT" Information Technology Company, Acquisition
(4) Bioinformatics Company Cooperation / Partnership
(5) Genomics Data-Base Company, M/A / Partnership
(6) University R&D Center, M/A / Professorship / Directorship
(7) Regional Center Uniqueness Cooperation / Directorship
Advantage: to offer a monopoly on FractoGene - putting HelixoMetry as well as a Geopolitical Region in lead position. Holding Stem Cell Patent for "Research & Development Uniqueness" is a key. First step was to have received anonymous offer from brokers to buy FractoGene. Second offer is to establish a "Central European Hospital" as a Hungarian Initiative, within "NewNATO Countries". Tools are Regional Investment, Regional Patent Intellectual Property Pool, Regional Clinical Trial. Overlaps with 1,2,3,4,5,6.
CENTRAL EUROPE ("NewNATO") (Talks started with inventor's homeland, SVNI Project, Hungary, 2001)
GERMANY (Talks started as inventor was awarded "Senior Distinguished US Scientist", German Humboldt Prize)
Max Planck Institut
GBF Jena
SINGAPORE
Genome Institute of Singapore
JAPAN
Riken
UK
Wellcome Genome Center
CHINA
Chinese National Genome Center, Sanghai